AI Robotics in Medicine

Simply Wall Street’s screener highlights Telescope Innovations, Profound Medical, and Perimeter Medical Imaging AI moving algorithms into real workflows—AI-enabled chemistry automation, MRI-guided incision-free ablation, and intraoperative tissue-margin imaging.

Revenues show traction (Telescope ≈CA$7. 3m largely U.S.; Profound ≈$18.

8m mostly U.S. with Canada and Germany; Perimeter ≈$2. 1m all Canada) alongside catalysts like Telescope’s recent Self Driving Lab supply agreements, growing TULSA interest at Profound, new board appointments, and a potential Telix collaboration.

The through-line is momentum tempered by financing risk: Telescope is loss-making with <1 year cash runway, and Profound remains loss-making funded by borrowing and new equity—watch whether interest and partnerships convert to durable sales before capital needs return.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Three AI healthcare players spotlighted for real-world clinical and lab uses

Simply Wall Street’s AI Healthcare screener spotlights three companies translating AI into clinical and lab workflows. Telescope Innovations applies AI-enabled lab automation and analytics to complex chemical and pharmaceutical reactions.

Profound Medical pairs AI software with MRI-guided, incision-free ablation systems for prostate and other targeted tissues; Perimeter Medical Imaging AI provides real-time, cross-sectional tissue margin views in the operating room.

Operationally, Telescope generates about CA$7. 3 million in chemical revenue, largely from the U.S., and has “recent agreements” to supply Self Driving Lab platforms to large pharma.

Profound posts about $18. 8 million in medical technology revenue, mostly U.S. ($12.

3m), with Canada ($5. 8m) and Germany ($0.

7m), amid growing TULSA interest, new board appointments, and a potential Telix Pharmaceuticals collaboration. Perimeter records about $2.

1 million in imaging revenue, all from Canada. Across the trio, traction meets risk: Telescope carries early-stage losses and less than a year of cash runway; Profound remains loss-making, funded by borrowing and fresh equity.

Key facts:

- Telescope revenue about CA$7.3 million from chemicals, mostly U.S., smaller Canada and Europe.

- Telescope signed recent agreements to supply Self Driving Lab platforms to large pharma clients.

- Profound Medical revenue about $18.8 million; U.S. $12.3m, Canada $5.8m, Germany $0.7m.

- Profound exploring potential Telix Pharmaceuticals collaboration and added new board appointments.

- Perimeter Medical Imaging AI revenue about $2.1 million, all from Canada.

Why it matters: Hospitals and surgeons could see more accurate, repeatable procedures as AI-guided ablation and intraoperative imaging mature, while pharma R&D may gain speed from self-driving lab deployments.

These use cases target efficiency and precision—key levers when health systems face cost pressures. For investors, the companies show rising commercial signals alongside financing risk.

Watch execution on Telescope’s supply agreements, Profound’s collaboration progress with Telix and board-led scaling efforts, and whether Perimeter expands beyond Canada. Adoption momentum versus cash runway and dilution remains the central trade-off.

Simplywall